Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News AHA 2016

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

Todd Neale

November 13, 2016

News Conference News ESC 2016

New Cardio-Oncology Position Statement Reviews Cardiovascular Side Effects of Cancer Therapies and Calls for Further Study

Shelley Wood

August 27, 2016

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Industry News

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

October 26, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Conference News ESC 2015

Danish Registry Study Shows Potential of Stroke Risk Score in Heart Failure Patients

L.A. McKeown

August 31, 2015

News Industry News

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

August 26, 2015

News Conference News Cell Therapy 2012

Novel Strategies Advance Cell Therapy for Cardiomyopathy

February 05, 2012

Advertisement

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

New Cardio-Oncology Position Statement Reviews Cardiovascular Side Effects of Cancer Therapies and Calls for Further Study

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Danish Registry Study Shows Potential of Stroke Risk Score in Heart Failure Patients

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

Novel Strategies Advance Cell Therapy for Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content